I agree that the Trustee (Marc P. Barmat) could have tried a little harder to determine a more realistic value of Generex's holdings (NGIO and Olaregen) and recover at least some money for creditors and investors. $3.5M (up from the original $1.5M) is a joke. The next joke is probably what we (dividend NGIO shareholders) get for our stake. Unfortunately, I only have myself to blame, because the signs of complete mismanagement and failure have been there all along (20+ years).